30
Participants
Start Date
January 12, 2020
Primary Completion Date
October 31, 2022
Study Completion Date
December 31, 2022
Pentoxifylline
The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
Erasmus MC Sophia Children's Hospital, Rotterdam
University Hospital Poznan, Poznan
Lead Sponsor
Erasmus Medical Center
OTHER